Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

IDE161

Source date not recordedAnalyse record ↗

PARG inhibitor in Phase 1 oncology studies as monotherapy and in combinations targeting DNA-damage-response dependencies.

Modality
oral small-molecule poly(ADP-ribose) glycohydrolase inhibitor
Availability (US)
Phase 1 monotherapy and pembrolizumab study Active, not recruiting; IDE849 combination study Recruiting
Biomarkers
dose-limiting toxicities; treatment-emergent adverse events; pharmacokinetics; pharmacodynamics; RECIST response
Hallmark targeted
genomic instability, DNA-damage response, replication stress
Kind
investigational drug
Clinical trials
NCT05787587 — Phase 1, Active, not recruiting on July 13, 2026 update; NCT07174583 — Phase 1/Phase 2, Recruiting on July 9, 2026 update